Premiplex

Premiplex (SHP607) is a recombinant human protein complex consisting of insulin-like growth factor 1 (rhIGF-1) and its primary binding protein, insulin-like growth factor-binding protein 3 (rhIGFBP-3). Originally developed by Premacure AB and later acquired by Shire (now part of Takeda), the therapy was designed as a systemic protein replacement to prevent retinopathy of prematurity (ROP) and other complications in extremely preterm infants. In utero, the fetus receives a continuous supply of IGF-1 from the mother; however, infants born very prematurely experience a sudden drop in IGF-1 levels, which is associated with abnormal vascular development in the retina and other organs. Premiplex aims to restore physiological IGF-1 levels to promote normal growth and prevent the pathological neovascularization characteristic of ROP. Despite reaching Phase II clinical trials, development was eventually discontinued by Takeda.

Brand names

Premiplex

Other names

mecasermin rinfabaterhIGF-1/rhIGFBP-3recombinant human insulin-like growth factor 1/insulin-like growth factor-binding protein 3 complex